TY - JOUR
T1 - 6315—S (Flomoxef) in respiratory tract infections
AU - Oizumi, Kohtaro
AU - Watanabe, Akira
AU - Aonuma, Seiichi
AU - Konno, Kiyoshi
AU - Saito, Akira
AU - Nagahama, Fumio
AU - Takebe, Kazuo
AU - Tamura, Masao
AU - Hayasi, Izumi
AU - Watanabe, Hazime
AU - Sihmomura, Jyutaroh
AU - Ujiie, Akira
AU - Takahori, Isao
AU - Hiraga, Yohmei
AU - Kikuchi, Kohki
AU - Kuroda, Rensuke
AU - Sekine, Kyuiciuroh
AU - Takagi, Hiroshi
AU - Tango, Mikiiiiko
AU - Abe, Morikuni
AU - Yamagishi, Ikuko
AU - Itoh, Choei
AU - Takeuchi, Keisuke
AU - Yajima, Osamu
AU - Kawamorita, Kiyoshi
AU - Ohnuma, Kikuo
AU - Yoshida, Tukasa
AU - Mizukosiii, Kazuo
AU - Yosiiizawa, Masayuki
AU - Shindom, Sauukoh
AU - Satom, Kazuo
AU - Nagai, Kohsaku
AU - Hasuike, Tekuo
AU - Umehara, Eijyu
AU - Sugawara, Yasuo
AU - Nishina, Moriaki
AU - Kohsaka, Shigemi
AU - Takizawa, Shigeo
AU - Matsumoto, Yuzuru
AU - Shikanai, Kenkichi
PY - 1987
Y1 - 1987
N2 - Clinical efficacy, bacteriological effects and safety of the parenteral oxacephem antibiotic 6315-S (Flomoxef) in treatment of respiratory infections were evaluated. In 78 patients (with acute bronchitis, 1; acute exacerbation of chronic bronchitis, 6; bacterial pneumonia, 56; bronchial pneumonia, 3; secondary infection in chronic respiratory disease, 7; pulmonary suppuration, 2; and other respiratory infections, 3) 6315-S was markedly effective in 15, effective in 42, slightly effective in 13 and ineffective in 8 patients. The efficacy rate was 73.1%. Fourteen cases (e. g., mycoplasma pneumoniae) were excluded as unevaluable. As causative organisms, 30 strains were detected: S. pneumoniae, 7; S. aureus, 5; Klebsiella spp., 4; Haemophilus influenzae, 4; and 10 other strains. Of 23 strains which could be evaluated bacteriologically, 17 were eliminated by administration of 6315-S. As regards safety, out of 92 patients treated, three developed allergic symptoms, such as exanthema, and one patient gastrointestinal symptoms. Thus frequency of side-effects was 4.4% (4/92). Abnormal laboratory values were found in 17 cases (18.5%): abnormal liver fuction test, 11, eosinophilia, 4; abnormal liver function with eosinophilia, 1; prolonged prothrombin time, 1. None of these changes was serious, all values having normalized soon after cessation of treatment.
AB - Clinical efficacy, bacteriological effects and safety of the parenteral oxacephem antibiotic 6315-S (Flomoxef) in treatment of respiratory infections were evaluated. In 78 patients (with acute bronchitis, 1; acute exacerbation of chronic bronchitis, 6; bacterial pneumonia, 56; bronchial pneumonia, 3; secondary infection in chronic respiratory disease, 7; pulmonary suppuration, 2; and other respiratory infections, 3) 6315-S was markedly effective in 15, effective in 42, slightly effective in 13 and ineffective in 8 patients. The efficacy rate was 73.1%. Fourteen cases (e. g., mycoplasma pneumoniae) were excluded as unevaluable. As causative organisms, 30 strains were detected: S. pneumoniae, 7; S. aureus, 5; Klebsiella spp., 4; Haemophilus influenzae, 4; and 10 other strains. Of 23 strains which could be evaluated bacteriologically, 17 were eliminated by administration of 6315-S. As regards safety, out of 92 patients treated, three developed allergic symptoms, such as exanthema, and one patient gastrointestinal symptoms. Thus frequency of side-effects was 4.4% (4/92). Abnormal laboratory values were found in 17 cases (18.5%): abnormal liver fuction test, 11, eosinophilia, 4; abnormal liver function with eosinophilia, 1; prolonged prothrombin time, 1. None of these changes was serious, all values having normalized soon after cessation of treatment.
UR - http://www.scopus.com/inward/record.url?scp=85007708265&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85007708265&partnerID=8YFLogxK
U2 - 10.11250/chemotherapy1953.35.Supplement1_541
DO - 10.11250/chemotherapy1953.35.Supplement1_541
M3 - Article
AN - SCOPUS:85007708265
VL - 35
SP - 541
EP - 561
JO - CHEMOTHERAPY
JF - CHEMOTHERAPY
SN - 0009-3165
ER -